Medicxi backs Chi­nese biotech's next-gen KRAS G12C drug with $40M in­jec­tion

The search for next-gen­er­a­tion KRAS drugs that can do what Am­gen and Bris­tol My­ers Squibb’s med­i­cines can’t has led to Medicxi’s first-ever in­vest­ment in Chi­na.

The Eu­ro­pean VC firm is pour­ing $40 mil­lion in­to Shang­hai-based D3 Bio, whose KRAS G12C in­hibitor is cur­rent­ly in Phase 2 tri­als for non-small cell lung can­cer, col­orec­tal can­cer and pan­cre­at­ic can­cer.

While Am­gen and Mi­rati (which was ac­quired by Bris­tol My­ers) made a ma­jor break­through by drug­ging KRAS G12C — a tar­get long con­sid­ered un­drug­gable — physi­cians are still hop­ing for bet­ter drugs, said Francesco de Ru­ber­tis, co-founder and part­ner at Medicxi, in an in­ter­view with End­points News. In par­tic­u­lar, he cit­ed the need for longer du­ra­tion of re­sponse, high­er re­sponse rates, depth of re­sponse and CNS pen­e­tra­tion of brain metas­tases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER